New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 20mg;   - modified release tablet - 20 mg - active: oxycodone hydrochloride 20mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide red macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 40mg;   - modified release tablet - 40 mg - active: oxycodone hydrochloride 40mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide red iron oxide yellow macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 80mg;   - modified release tablet - 80 mg - active: oxycodone hydrochloride 80mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide yellow macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - olmesartan medoxomil - film coated tablet - 40 milligram - olmesartan medoxomil

United States - English - NLM (National Library of Medicine)

barr laboratories inc. - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate 1.25 mg - mas-er capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of mas-er capsules in the treatment of adhd was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met dsm-iv® criteria for adhd [see clinical studies (14)] . a diagnosis of adhd (dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure t

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; hyprolose; microcrystalline cellulose - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.